Literature DB >> 16723596

Clinical correlation of the CLSI susceptibility breakpoint for piperacillin- tazobactam against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella species.

Patrick J Gavin1, Mira T Suseno, Richard B Thomson, J Michael Gaydos, Carl L Pierson, Diane C Halstead, Jaber Aslanzadeh, Stephen Brecher, Coleman Rotstein, Stephen E Brossette, Lance R Peterson.   

Abstract

We assessed infections caused by extended-spectrum-beta-lactamase-producing Escherichia coli or Klebsiella spp. treated with piperacillin-tazobactam to determine if the susceptibility breakpoint predicts outcome. Treatment was successful in 10 of 11 nonurinary infections from susceptible strains and in 2 of 6 infections with MICs of >16/4 mug/ml. All six urinary infections responded to treatment regardless of susceptibility.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16723596      PMCID： PMC1479103          DOI： 10.1128/AAC.00381-05

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  27 in total

1.  Fatal infection due to extended-spectrum beta-lactamase-producing Escherichia coli: implications for antibiotic choice for spontaneous bacterial peritonitis.

Authors:  D L Paterson; N Singh; T Gayowski; I R Marino
Journal:  Clin Infect Dis       Date:  1999-03       Impact factor: 9.079

2.  Pharmacodynamic profiling of piperacillin in the presence of tazobactam in patients through the use of population pharmacokinetic models and Monte Carlo simulation.

Authors:  Thomas P Lodise; Ben Lomaestro; Keith A Rodvold; Larry H Danziger; George L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

3.  The inoculum effect: fact or artifact?

Authors:  William A Craig; Sujata M Bhavnani; Paul G Ambrose
Journal:  Diagn Microbiol Infect Dis       Date:  2004-12       Impact factor: 2.803

4.  Treatment failure due to extended spectrum beta-lactamase.

Authors:  J A Karas; D G Pillay; D Muckart; A W Sturm
Journal:  J Antimicrob Chemother       Date:  1996-01       Impact factor: 5.790

5.  Pharmacokinetics and pharmacodynamics of two multiple-dose piperacillin-tazobactam regimens.

Authors:  D J Occhipinti; S L Pendland; L L Schoonover; E B Rypins; L H Danziger; K A Rodvold
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

6.  Clinical characteristics and molecular epidemiology associated with imipenem-resistant Klebsiella pneumoniae.

Authors:  M Ahmad; C Urban; N Mariano; P A Bradford; E Calcagni; S J Projan; K Bush; J J Rahal
Journal:  Clin Infect Dis       Date:  1999-08       Impact factor: 9.079

7.  Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy.

Authors:  Cheol-In Kang; Sung-Han Kim; Wan Beom Park; Ki-Deok Lee; Hong-Bin Kim; Eui-Chong Kim; Myoung-Don Oh; Kang-Won Choe
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

8.  Ceftazidime-resistant Klebsiella pneumoniae isolates recovered at the Cleveland Department of Veterans Affairs Medical Center.

Authors:  L B Rice; E C Eckstein; J DeVente; D M Shlaes
Journal:  Clin Infect Dis       Date:  1996-07       Impact factor: 9.079

9.  Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella.

Authors:  J J Rahal; C Urban; D Horn; K Freeman; S Segal-Maurer; J Maurer; N Mariano; S Marks; J M Burns; D Dominick; M Lim
Journal:  JAMA       Date:  1998-10-14       Impact factor: 56.272

Review 10.  The pharmacodynamics of beta-lactams.

Authors:  J D Turnidge
Journal:  Clin Infect Dis       Date:  1998-07       Impact factor: 9.079
View more
  18 in total

1.  In vivo comparison of CXA-101 (FR264205) with and without tazobactam versus piperacillin-tazobactam using human simulated exposures against phenotypically diverse gram-negative organisms.

Authors:  Catharine C Bulik; Pamela R Tessier; Rebecca A Keel; Christina A Sutherland; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2011-11-07       Impact factor: 5.191

2.  Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment.

Authors:  Mario Tumbarello; Maurizio Sanguinetti; Eva Montuori; Enrico M Trecarichi; Brunella Posteraro; Barbara Fiori; Rita Citton; Tiziana D'Inzeo; Giovanni Fadda; Roberto Cauda; Teresa Spanu
Journal:  Antimicrob Agents Chemother       Date:  2007-03-26       Impact factor: 5.191

3.  Piperacillin-Tazobactam Versus Carbapenems for the Treatment of Nonbacteremic Urinary Tract Infections due to Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae.

Authors:  Jordan Brooke Tullos; Laura Leigh Stoudenmire; Jonathon David Pouliot
Journal:  Hosp Pharm       Date:  2018-12-07

Review 4.  Current concepts in antimicrobial therapy against resistant gram-negative organisms: extended-spectrum beta-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa.

Authors:  Souha S Kanj; Zeina A Kanafani
Journal:  Mayo Clin Proc       Date:  2011-03       Impact factor: 7.616

5.  Is Piperacillin-Tazobactam Effective for the Treatment of Pyelonephritis Caused by Extended-Spectrum β-Lactamase-Producing Organisms?

Authors:  Sima L Sharara; Joe Amoah; Zoi D Pana; Patricia J Simner; Sara E Cosgrove; Pranita D Tamma
Journal:  Clin Infect Dis       Date:  2020-11-05       Impact factor: 9.079

6.  Impact of the MIC of piperacillin-tazobactam on the outcome of patients with bacteremia due to extended-spectrum-β-lactamase-producing Escherichia coli.

Authors:  Pilar Retamar; Lorena López-Cerero; Miguel Angel Muniain; Álvaro Pascual; Jesús Rodríguez-Baño
Journal:  Antimicrob Agents Chemother       Date:  2013-04-22       Impact factor: 5.191

7.  ESBL Detection: Comparison of a Commercially Available Chromogenic Test for Third Generation Cephalosporine Resistance and Automated Susceptibility Testing in Enterobactericeae.

Authors:  Mohamed Ramadan El-Jade; Marijo Parcina; Ricarda Maria Schmithausen; Christoph Stein; Alina Meilaender; Achim Hoerauf; Ernst Molitor; Isabelle Bekeredjian-Ding
Journal:  PLoS One       Date:  2016-08-05       Impact factor: 3.240

Review 8.  The Use of Noncarbapenem β-Lactams for the Treatment of Extended-Spectrum β-Lactamase Infections.

Authors:  Pranita D Tamma; Jesus Rodriguez-Bano
Journal:  Clin Infect Dis       Date:  2017-04-01       Impact factor: 9.079

Review 9.  The continuing challenge of ESBLs.

Authors:  Federico Perez; Andrea Endimiani; Kristine M Hujer; Robert A Bonomo
Journal:  Curr Opin Pharmacol       Date:  2007-09-17       Impact factor: 5.547

10.  Treatment of complicated urinary tract infections with an emphasis on drug-resistant gram-negative uropathogens.

Authors:  Matthew E Levison; Donald Kaye
Journal:  Curr Infect Dis Rep       Date:  2013-04       Impact factor: 3.725
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.